Wallace L. Akerley

Wallace L. Akerley, MD

Languages spoken: English

Academic Information

Departments Primary - Internal Medicine

Divisions: Oncology

Board Certification

  • American Board of Internal Medicine (Internal Medicine)
  • American Board of Internal Medicine (Sub: Hematology)
  • National Board of Medical Examiners
  • American Board of Internal Medicine (Sub: Medical Oncology)

Wallace Akerley, MD is a medical oncologist with greater than 30 years experience as a principal investigator on numerous clinical research trials who actively cares for patients with lung cancer. He is the chairman of the Protocol Review and Monitoring Committee at Huntsman Cancer Institute (HCI), Director of the Lung Cancer Disease Center of Excellence at HCI and member of the NCCN's Steering Committee for Small Cell Lung Cancer Panel and NSCLC Panel.

Research Statement

Clinical research, treating patients with the investigational therapies, is the final and most important step of cancer research. Identifying new and improved and/or better tolerated therapy is the primary wish of every cancer physician. There has been a gratifying number of new cancer therapies that were evaluated at HCI and FDA approved in the recent past.

Education History

Undergraduate Boston University
 BS
Professional Medical Brown University
 MD
Internship University of Southern California
 Intern
Residency University of Southern California
 Resident
Fellowship University of Southern California
 Fellow
Fellowship Dartmouth Hitchcock Medical Ctr.
 Fellow

Selected Publications

Journal Article

  1. Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H (2000). Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol, 174(1), 57-9.
  2. Posner M, Martin A, Slapak CA, Clark JW, Cummings FJ, Robert NJ, Sikov W, Akerley W (1992). A phase II trial of continuous infusion cisplatin and 5-fluorouracil with oral calcium leucovorin in colorectal carcinoma. Am J Clin Oncol, 15(3), 239-41.
  3. Oliver TG, Patel J, Akerley W (2015). Squamous non-small cell lung cancer as a distinct clinical entity. Am J Clin Oncol, 38(2), 220-6.
  4. Herde RF, Kokeny KE, Reddy CB, Akerley WL, Hu N, Boltax JP, Hitchcock YJ (2015). Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience. Am J Clin Oncol, 41(1), 24-29.
  5. Dupuy D, Zagoria R, Akerley W, Mayo-Smith W, Kavanagh P, Safran H. (2000). Percutaneous Radiofrequency Ablation of Malignancies in the Lung. Am J Roentgenol Radium Ther Nucl Med, 174(1), 57-9.
  6. Wanebo HJ, Chougule P, Akerley WL 3rd, Koness RJ, McRae R, Nigri P, Leone L, Ready N, Safran H, Webber B, Cole B (1997). Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer. Am J Surg, 174(5), 518-22.
  7. Akerley WL 3rd, Moritz TE, Ryan LS, Henderson WG, Zacharski LR (1993). Racial comparison of outcomes of male Department of Veterans Affairs patients with lung and colon cancer. Arch Intern Med, 153(14), 1681-8.
  8. Akerley WL 3rd, Guyre PM, Davis BH (1991). Neutrophil activation through high-affinity Fc gamma receptor using a monomeric antibody with unique properties. Blood, 77(3), 607-15.
  9. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O'Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell S (2001). Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. British journal of cancer, 84(2), 157-63.
  10. Socinski MA, Zhang C, Herndon JE 2nd, Dillman RO, Clamon G, Vokes E, Akerley W, Crawford J, Perry MC, Seagren SL, Green M (2004). Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Annals of oncology, 15(7), 1033-41.
  11. Grunberg SM, Akerley WL, Krailo MD, Johnson KB, Baker CR, Cariffe P (1986). Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. Cancer investigation, 4(5), 379-85.
  12. Glantz MJ, Hall WA, Cole BF, Chozick BS, Shannon CM, Wahlberg L, Akerley W, Marin L, Choy (1995). Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer, 75(12), 2919-31.
  13. King TC, Akerley W, Fan AC, Moore T, Mangray S, Hsiu Chen M, Safran (2000). p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer, 89(4), 769-73.
  14. Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone (2002). A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer, 94(6), 1654-60.
  15. Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green M (2003). Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer, 97(10), 2480-6.
  16. Akerley W, Safran H, Zaner K, Ready N, Mega T, Kennedy (2006). Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. Cancer, 107(5), 1050-4.
  17. Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone L (2002). A Multiinstitutional, Concurrent Chemoradiation Trial of Strontium-89, Estramustine, and Vinblastine for Hormone Refractory Prostate Carcinoma Involving Bone. Cancer, 94(6), 1654-1660.
  18. King T, Akerley W, Fan A, Walsh K, Mangray S, Chen M, Safran H (2000). P53 Mutations Do Not Predict Response to Paclitaxel for Metastatic Non-Small Cell Lung Cancer. Cancer, 89(4), 769-73.
  19. Gurevich I, Akerley W (2001). Treatment of the Jaundiced Patient with Breast Carcinoma. Cancer, 91(4), 660-663.
  20. Akerley W (2000). Secondary Leukemia: Twice is a Coincidence?. Cancer, 88(3), 497-9.
  21. Akerley W, Rathore R, Ready N, Leone L, Sikov W, Safran H, Kennedy T (2002). A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. Cancer, 95(9), 2000-5.
  22. Akerley W, Herndon J, Green M, et al (2003). Dose-Dense Weekly Paclitaxel and Pharmacologic Evaluation for Patients with Stage IIIB-IV Non-Small Cell Lung Cancer: A Phase II Trial of Cancer and Leukemia Group B (CALGB 9731/9765). Cancer, 97, 2480-6.
  23. Akerley W, Rathore R, Ready N, Leone L, Sikov W, Safran H, Kennedy (2002). A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. Cancer, 95(9), 2000-5.
  24. Akerley W 3r (2000). Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule. Chest, 117(4 Suppl 1), 152S-155S.
  25. Akerley W (2000). Paclitaxel in Advanced Non-small Cell Lung Cancer: An Alternative High-dose Weekly Schedule. Chest, 117:4 (suppl 1), 152-5.
  26. Akerley WL, Nelson RE, Cowie RH, Spinella DG, Hornberger (2013). The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer. Current medical research and opinion, 29(5), 517-25.
  27. Akerley WL, Arnaud AM, Reddy B, Page R (2017). Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer. Current medical research and opinion, 33(6), 1091-1097.
  28. Kim DW, Shyr Y, Chen H, Akerley W, Johnson DH, Choy (2005). Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer. International journal of radiation oncology, biology, physics, 63(4), 1029-36.
  29. Clark J, Sikov W, Cummings F, Browne M, Akerley W, Wanebo H, Weitberg A, Kennedy T, Cole B, Bigley J, Beitz J, Darnowski (1996). Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. Journal of cancer research and clinical oncology, 122(9), 554-8.
  30. Grunberg SM, Ehler E, McDermed JE, Akerley W (1988). Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin. Journal of the National Cancer Institute, 80(11), 864-8.
  31. Blackstock AW, Herndon JE 2nd, Paskett ED, Perry MC, Graziano SL, Muscato JJ, Kosty MP, Akerley WL, Holland J, Fleishman S, Green M (2002). Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. Journal of the National Cancer Institute, 94(4), 284-90.
  32. Blackstock A, Herndon J, Paskett E, Perry M, Graziano S, Muscato, Kosty M, Akerley W, Holland J, Fleishman S, Green M (2002). Outcomes Among African-American and Non African-American Patients with Advanced Non-Small Cell Lung Cancer: A Report from the CALGB. Journal of the National Cancer Institute, 94(4), 284-90.
  33. Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone (1994). Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. Journal of clinical oncology, 12(12), 2682-6.
  34. Safran H, King TP, Choy H, Hesketh PJ, Wolf B, Altenhein E, Sikov W, Rosmarin A, Akerley W, Radie-Keane K, Cicchetti G, Lopez F, Bland K, Wanebo H (1997). Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. Journal of clinical oncology, 15(3), 901-7.
  35. Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P, Leone (1998). Phase I trial of weekly paclitaxel in advanced lung cancer. Journal of clinical oncology, 16(1), 153-8.
  36. Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P, Egorin M (1998). High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?. Journal of clinical oncology, 16(4), 1561-7.
  37. Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy (1998). Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Journal of clinical oncology, 16(10), 3316-22.
  38. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller J (2006). Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. Journal of clinical oncology, 24(31), 5025-33.
  39. Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green M (2007). Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. Journal of clinical oncology, 25(13), 1698-704.
  40. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley (2009). Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. Journal of clinical oncology, 27(31), 5255-61.
  41. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, Ramlau R, Arthur S, Gorbachevsky I, Schwartz B, Schiller J (2011). Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. Journal of clinical oncology, 29(24), 3307-15.
  42. Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz (2015). Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of clinical oncology, 33(24), 2667-74.
  43. Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel (2016). Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. Journal of clinical oncology, 34(31), 3740-3748.
  44. Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ Jr, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang (2017). Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. Journal of clinical oncology, 35(25), 2885-2892.
  45. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ (2001). Phase II Study of Docetaxel, Estramustine, and Low-dose Hydrocortisone in Men with Hormone-refractory Prostate Cancer: a final report of CALGB 9780. Journal of clinical oncology, 19(9), 2509-16.
  46. Francis S, Orton A, Stoddard G, Tao R, Hitchcock YJ, Akerley W, Kokeny K (2018). Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer. Journal of clinical oncology, 36(4), 333-341.
  47. Recht LD, Glantz MJ, Meitner P, Glantz L, Akerley W, Wahlberg L, Saris S, Cole B (1998). Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC). Journal of neuro-oncology, 36(3), 201-8.
  48. Grossmann KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, De Groot JF, Aiken RD, Olson JJ, Evans BA, Jensen R (2012). Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. Journal of neuro-oncology, 110(2), 257-64.
  49. Makarovskiy A, Ackerley W, Wojcik W, Halpert G, Stein B, Carreiro M, Hixson D (1997). Application of Immunomagnetic Beads in Combination with RT-PCR for the Detection of Circulating Prostate Cancer Cells. Journal of clinical laboratory analysis, 11, 346-50.
  50. Poruk KE, Firpo MA, Boucher KM, Akerley WL, Neumayer LA, Sklow B, Scaife CL, Mulvihill S (2012). Assessment of Serum Platelet Factor 4 as a Predictive Marker for VTE and as a Prognostic Biomarker in Pancreatic, Colorectal, Breast, and Lung Cancer. The Journal of surgical research, 172(2), 242-243.
  51. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba W (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine, 363(8), 711-23.
  52. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group, Akerley WL (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine, 2011 Jun(364(26):), 2507-16.
  53. Glantz MJ, Cole BF, Friedberg MH, Lathi E, Choy H, Furie K, Akerley W, Wahlberg L, Lekos A, Louis (1996). A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology, 46(4), 985-91.
  54. Glantz M, Kim L, Choy H, Akerley W (1999). Concurrent Chemotherapy and Radiotherapy in Patients with Brain Tumors. Oncology, 13(10) suppl 5, 78-82.
  55. Glantz MJ, Choy H, Kearns CM, Akerley W, Egorin M (1995). Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions. Seminars in oncology, 22(5 Suppl 12), 26-32.
  56. Akerley W 3rd, Glantz M, Choy (1996). Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer. Seminars in oncology, 23(5 Suppl 12), 14-8.
  57. Akerley (1996). Phase I/II trial of weekly paclitaxel in patients with advanced lung cancer. Seminars in oncology, 23(6 Suppl 16), 55-8.
  58. Choy H, Akerley W, Safran H, Graziano S, Chung (1996). Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer. Seminars in oncology, 23(6 Suppl 16), 117-9.
  59. Glantz MJ, Choy H, Akerley W, Kearns CM, Egorin MJ, Rhodes CH, Cole B (1996). Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response. Seminars in oncology, 23(6 Suppl 16), 128-35.
  60. Akerley W, Choy H, Safran H, Sikov W, Rege V, Sambandam S, Wittels (1997). Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Seminars in oncology, 24(4 Suppl 12), S12-10-S12-13.
  61. Akerley W, Sikov WM, Cummings F, Safran H, Strenger R, Marchant (1997). Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. Seminars in oncology, 24(5 Suppl 17), S17-87-S17-90.
  62. Chougule P, Wanebo H, Akerley W, McRae R, Nigri P, Leone L, Safran H, Ready N, Koness RJ, Radie-Keane K, Cole (1997). Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results. Seminars in oncology, 24(6 Suppl 19), S19-57-S19-61.
  63. Glantz M, Choy H, Akerley W, Kearns C, Egorin M, Rhodes H, Cole B (1996). Weekly Paclitaxel With and Without Concurrent Radiation Therapy: Toxicity, Pharmacokinetics and Response. Seminars in oncology, 23(6) Suppl 16, 128-135.
  64. Akerley W, Glantz M, Choy H (1996). Phase I Study of Weekly Outpatient Paclitaxel in Advanced and Metastatic Non-small Cell Lung Cancer. Seminars in oncology, 23(5), Suppl 12, 14-18.
  65. Carr SR, Akerley W, Hashibe M, Cannon-Albright L (2015). Evidence for a genetical contribution to non-smoking-related lung cancer. Thorax, 70(11), 1033-9.
  66. Miller ME, Dores GM, Thorpe SL, Akerley W (1994). Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thrombosis research, 74(6), 577-94.
  67. Akerley W, Choy (1995). Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 12 Suppl 2, S107-15.
  68. Clamon G, Herndon J, Akerley W, Green (1998). Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B. Lung cancer (Amsterdam, Netherlands), 19(1), 25-9.
  69. Kim DW, Shyr Y, Shaktour B, Akerley W, Johnson DH, Choy (2005). Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 50(2), 235-45.
  70. Akerley W, Boucher K, Rich N, Egbert L, Harker G, Bylund J, Van Duren T, Reddy (2013). A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung cancer (Amsterdam, Netherlands), 79(3), 307-11.
  71. Nelson RE, Stenehjem D, Akerley (2013). A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. Lung cancer (Amsterdam, Netherlands), 82(3), 461-8.
  72. Choy H, Akerley W, Safran H, Graziano S (1997). Concurrent Weekly Paclitaxel and Radiation Therapy for Locally Advanced NSCLC. Lung cancer (Amsterdam, Netherlands), 18(S2), 152.
  73. Chalmers A, Jensen L, Akerley (2017). Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report. Lung cancer (Amsterdam, Netherlands), 114, 68-69.
  74. Wanebo H, Chougule P, Ready N, Safran H, Akerley W, Koness R, McRae R, Nigri P, Leone L, Kennedy T, Webber B (2001). Surgical Resection is Necessary to Maximize Tumor Control In Function Preserving, Aggressive Chemoradiation Protocols for Advanced Squamous Cancer of the Head and Neck (Stage III and IV). Annals of surgical oncology, 8, 644-50.
  75. Choy H, Safran H, Akerley W, Graziano SL, Bogart JA, Cole B (1998). Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clinical cancer research, 4(8), 1931-6.
  76. Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL 3rd, Othus M, Sosman JA, Kirkwood JM, Sondak V (2012). Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clinical cancer research, 18(4), 1129-37.
  77. Makarovskiy A, Siryaporn E, Hixon D, Akerley W (2002). Survival of Docetaxel-resistant Prostate Cancer Cells Depends on Phenotype Alterations and Continuity of Drug Exposure. Cellular and molecular life sciences, 59, 1198-1211.
  78. Chougule PB, Akhtar MS, Akerley W, Ready N, Safran H, McRae R, Nigri P, Bellino J, Koness J, Radie-Keane K, Wanebo (1999). Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study. Seminars in radiation oncology, 9(2 Suppl 1), 58-63.
  79. Wanebo HJ, Chougule P, Ready N, Koness RJ, Akerley W, McRae R, Nigri P, Leone L, Webber B, Safran (1999). Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV). Seminars in radiation oncology, 9(2 Suppl 1), 77-84.
  80. Akerley W, Choy (1999). Single-agent paclitaxel and radiation for non-small cell lung cancer. Seminars in radiation oncology, 9(2 Suppl 1), 85-9.
  81. Wanebo H, Chougule P, Ready N, Koness R, Akerley W, McRae R, Nigri P, Leone L, Webber B, Safran H (1999). Preoperative Paclitaxel, Carboplatin and Radiation Therapy in Advanced Head and Neck Cancer. Seminars in radiation oncology, 9(2) suppl 1, 77-84.
  82. Choy H, King T, Akerley W, Safran H (1997). Paclitaxel and Concurrent Radiation for Lung, Pancreatic and Gastric Carcinomas: Significance of p53 Gene Mutations for Treatment Response. Seminars in radiation oncology, 7(3), s77-81.
  83. Akerley W and Choy H (1999). Single Agent Paclitaxel and Radiation for Non-Small Cell Lung Cancer. Seminars in radiation oncology, 9(2) suppl 1, 85-89.
  84. Chougule P, Akhtar M, Akerley W, Ready N, Safran H, McRae R, Nigri P, Bellino J, Koness R, Radie-Kane K, and Wanebo H (1999). Chemoradiotherapy for Advanced Inoperable Head and Neck Cancer: A Phase II Study. Seminars in radiation oncology, 9(2) suppl 1, 58-63.
  85. Chalmers A, Cannon L, Akerley (2019). Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. The oncologist, 24(7), 963-972.
  86. Buttigliero C, Shepherd FA, Barlesi F, Schwartz B, Orlov S, Favaretto AG, Santoro A, Hirsh V, Ramlau R, Blackler AR, Roder J, Spigel D, Novello S, Akerley W, Scagliotti G (2019). Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. The oncologist, 24(6), e251-e259.
  87. Choy H, Akerley W, Glantz M, Safran H, Graziano S, Chung (1996). Concurrent Paclitaxel and Radiation Therapy for Solid Tumors. Cancer control, 3(4), 310-318.
  88. Akerley (2001). Recent developments in weekly paclitaxel therapy in lung cancer. Current oncology reports, 3(2), 165-9.
  89. Akerley W (2001). Recent Development in Weekly Paclitaxel Therapy of Lung Cancer. Current oncology reports, 3(2), 165-169.
  90. Ou JY, Fowler B, Ding Q, Kirchhoff AC, Pappas L, Boucher K, Akerley W, Wu Y, Kaphingst K, Harding G, Kepka (2018). A statewide investigation of geographic lung cancer incidence patterns and radon exposure in a low-smoking population. BMC cancer, 18(1), 115.
  91. Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami P (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC cancer, 21(1), 510.
  92. Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner C (2014). Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. International journal of gynecological cancer, 24(9), 1583-9.
  93. Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock (2010). Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Molecular cancer therapeutics, 9(12), 3410-9.
  94. Akerley W, Herndon JE Jr, Lyss AP, Choy H, Turrisi A, Graziano S, Williams T, Zhang C, Vokes EE, Green M (2005). Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. Clinical lung cancer, 7(1), 47-53.
  95. Ettinger DS, Akerley W, Bepler G, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Figlin RA, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Patel JD, Robert F, Sugarbaker DJ, Wood D (2008). Non-small cell lung cancer. Journal of the National Comprehensive Cancer Network, 6(3), 228-69.
  96. Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC J (2008). Small cell lung cancer. Journal of the National Comprehensive Cancer Network, 6(3), 294-314.
  97. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC, NCCN Non-Small Cell Lung Cancer Panel Members (2010). Non-small cell lung cancer. Journal of the National Comprehensive Cancer Network, 8(7), 740-801.
  98. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, National Comprehensive Cancer Network (2010). Thymic malignancies. Journal of the National Comprehensive Cancer Network, 8(11), 1302-15.
  99. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC Jr, National Comprehensive Cancer Network (2011). Small cell lung cancer. Journal of the National Comprehensive Cancer Network, 9(10), 1086-113.
  100. Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, National Comprehensive Cancer Network (2012). Malignant pleural mesothelioma. Journal of the National Comprehensive Cancer Network, 10(1), 26-41.
  101. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW Jr, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM, NCCN (National Comprehensive Cancer Network) (2012). Non-small cell lung cancer. Journal of the National Comprehensive Cancer Network, 10(10), 1236-71.
  102. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW Jr, Merritt RE, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC Jr, Gregory K, Hughes M, National Comprehensive Cancer Network (2013). Small cell lung cancer. Journal of the National Comprehensive Cancer Network, 11(1), 78-98.
  103. Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, National Comprehensive Cancer Network (2013). Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 11(5), 562-76.
  104. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, National comprehensive cancer network (2013). Non-small cell lung cancer, version 2.2013. Journal of the National Comprehensive Cancer Network, 11(6), 645-53; quiz 653.
  105. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes (2014). Non-small cell lung cancer, version 1.2015. Journal of the National Comprehensive Cancer Network, 12(12), 1738-61.
  106. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M, National comprehensive cancer network (2015). Non-Small Cell Lung Cancer, Version 6.2015. Journal of the National Comprehensive Cancer Network, 13(5), 515-24.
  107. Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE 3rd, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ Jr, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart F (2015). NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. Journal of the National Comprehensive Cancer Network, 13(11), 1337-46.
  108. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes (2016). NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. Journal of the National Comprehensive Cancer Network, 14(3), 255-64.
  109. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes (2016). NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. Journal of the National Comprehensive Cancer Network, 14(7), 825-36.
  110. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes (2017). Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 15(4), 504-535.
  111. Akerley (2017). Biomarker-Based Treatment Selection in Non-Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network, 15(5S), 689-691.
  112. Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, fossella F, Grecula JC et al (2008). Small cell lung cancer. Journal of the National Comprehensive Cancer Network, 6(3), 294-314.
  113. Ettinger DS, Akerley W, Bepler G, Chang A, cheney Rt, Chirieac LR, D'Amico TA, Demmy TL et al (2008). Non-small cell lung cancer. Journal of the National Comprehensive Cancer Network, 6(3), 228-269.
  114. Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Santana-Davila R, Williams CC, Hoffmann KG, Hughes (2018). NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. Journal of the National Comprehensive Cancer Network, 16(10), 1171-1182.
  115. Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes (2018). NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. Journal of the National Comprehensive Cancer Network, 16(7), 807-821.
  116. Akerley W, McCoy J, Hesketh PJ, Goodwin JW, Bearden JD, Atkins JN, Chansky K, Crowley JJ, Gandara DR, SWOG (2007). Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. Journal of thoracic oncology, 2(6), 526-30.
  117. Akerley W, Boucher KM, Bentz JS, Arbogast K, Walters (2009). A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. Journal of thoracic oncology, 4(2), 214-9.
  118. Stinchcombe TE, Hodgson L, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Niell HB, Atkins JN, Akerley W, Green MR, Vokes EE, Cancer and Leukemia Group B (2009). Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. Journal of thoracic oncology, 4(9), 1117-25.
  119. Lara PN Jr, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL 3rd, Hirsch FR, Mack PC, Gandara D (2016). SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. Journal of thoracic oncology, 11(3), 420-5.
  120. Cannon-Albright LA, Carr SR, Akerley (2019). Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer. Journal of thoracic oncology, 14(7), 1184-1191.
  121. Carr SR, Akerley W, Cannon-Albright L (2018). Genetic Contribution to Nonsquamous, Non-Small Cell Lung Cancer in Nonsmokers. Journal of thoracic oncology, 13(7), 938-945.
  122. Scagliotti GV, Shuster D, Orlov S, von Pawel J, Shepherd FA, Ross JS, Wang Q, Schwartz B, Akerley (2018). Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study. Journal of thoracic oncology, 13(6), 849-854.
  123. Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Targeted oncology, 14(4), 417-421.
  124. Morris BB, Wages NA, Grant PA, Stukenberg PT, Gentzler RD, Hall RD, Akerley WL, Varghese TK, Arnold SM, Williams TM, Coppola V, Jones DR, Auble DT, Mayo M (2021). MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma. Frontiers in oncology, 10, 585551.
  125. Gubens MA, Chuang JC, Akerley W, Langer CJ, Clément-Duchêne C, San Pedro-Salcedo M, Colevas AD, Dragnev K, Socinski MA, Wakelee H (2018). A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. Journal of thoracic disease, 10(1), 219-227.
  126. Rich P, Mitchell RB, Schaefer E, Walker PR, Dubay JW, Boyd J, Oubre D, Page R, Khalil M, Sinha S, Boniol S, Halawani H, Santos ES, Brenner W, Orsini JM, Pauli E, Goldberg J, Veatch A, Haut M, Ghabach B, Bidyasar S, Quejada M, Khan W, Huang K, Traylor L, Akerley (2021). Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer. Journal for immunotherapy of cancer, 9(10),
  127. Samadder NJ, Smith KR, Hanson H, Pimentel R, Wong J, Boucher K, Akerley W, Gilcrease G, Ulrich CM, Burt RW, Curtin (2016). Familial Risk in Patients With Carcinoma of Unknown Primary. JAMA oncology, 2(3), 340-6.
  128. Choy H, Akerley W, Devore R (1997). Paclitaxel in Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. 13(4), 17-24.
  129. Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L (1997). Phase I Trial of Outpatient Weekly Paclitaxel and Concurrent Radiation Therapy for Advanced Non-Small Cell Lung Cancer. 2(1), 167-71.
  130. Akerley W (1998). Oncology: Combined Modalilty Therapy in Non-Small Cell Lung Cancer. 2(3), 14-15.
  131. Akerley W, Edwards S, Wilson R, Van Duren T, Akerley D, Tranter S, Sharry (2011). Awareness of Radon - Associated Health Risks in Utah. 16(2011), 58-60.
  132. Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich C (2022). Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. The Journal of rural health, 38(4), 886-899.
  133. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples A (2022). Factors associated with changes in exercise behaviors during the COVID-19 pandemic. Cancer causes & control, 33(7), 939-950.
  134. Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, Dillon PM, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VF, Akerley WL, Gentzler RD, Hall RD, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo M (2022). Replicative Instability Drives Cancer Progression. Biomolecules, 12(11),
  135. Rudin CM, Pandha HS, Zibelman M, Akerley WL, Harrington KJ, Day D, Hill AG, O'Day SJ, Clay TD, Wright GM, Jennens RR, Gerber DE, Rosenberg JE, Ralph C, Campbell DC, Curti BD, Merchan JR, Ren Y, Schmidt EV, Guttman L, Gupta (2023). Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. Journal for immunotherapy of cancer, 11(1),
  136. Gadgeel SM, Miao J, Riess JW, Moon J, Mack PC, Gerstner GJ, Burns TF, Taj A, Akerley WL, Dragnev KH, Laudi N, Redman MW, Gray JE, Gandara DR, Kelly (2023). Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042). Clinical cancer research,
  137. McCarty RD, Barnard ME, Lawson-Michod KA, Owens M, Green SE, Derzon S, Karabegovic L, Akerley WL, Watt MH, Doherty JA, Grieshober (2023). Pathways to lung cancer diagnosis among individuals who did not receive lung cancer screening: a qualitative study. BMC primary care, 24(1), 203.
  138. Mitzman B, Varghese TK Jr, Akerley WL, Nelson R (2024). Surgical-decision making in the setting of unsuspected N2 disease: a cost-effectiveness analysis. Journal of thoracic disease, 16(2), 1063-1073.
  139. Aßmann ES, Ose J, Hathaway CA, Oswald LB, Hardikar S, Himbert C, Chellam V, Lin T, Daniels B, Kirchhoff AC, Gigic B, Grossman D, Tward J, Varghese TK Jr, Shibata D, Figueiredo JC, Toriola AT, Beck A, Scaife C, Barnes CA, Matsen C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Grady WM, Schneider M, Dinkel A, Islam JY, Gonzalez BD, Otto AK, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples A (2024). Risk factors and health behaviors associated with loneliness among cancer survivors during the COVID-19 pandemic. Journal of behavioral medicine, 47(3), 405-421.
  140. Jo Y, Puri S, Haaland B, Coletta AM, Chipman JJ, Embrey K, Kerrigan KC, Patel SB, Moynahan K, Gumbleton M, Akerley W (2025). Augmenting Prognostication: Utilizing Activity Trackers to Enhance Survival Prediction in Metastatic Non-Small Cell Lung Cancer. Clinical lung cancer, 26(1), 29-38.

Review

  1. Sandler A, Hirsh V, Reck M, von Pawel J, Akerley W, Johnson D (2012). An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. Lung cancer (Amsterdam, Netherlands), 78(1), 1-7.

Editorial

  1. Chalmers AW, Patel SB, Akerley (2018). Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?. Journal of thoracic disease, 10(3), 1198-1200.

Letter

  1. Chalmers A, Akerley (2017). Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-Naïve, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice. Journal of clinical oncology, 35(20), 2340.

Other

  1. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples A (2021). Impact of the COVID-19 pandemic on exercise habits among cancer patients.

News & Podcasts

Huntsman Cancer Institute News